Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy
June 27 2016 - 8:00AM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative medicines to people with
renal disease, today announced that Douglas Jermasek will join the
company as vice president, marketing and strategy, effective July
1, 2016. In this role, he will be responsible for brand strategy,
product positioning, marketing, market access, and patient services
for the company’s lead medicine, Auryxia® (ferric citrate).
“Doug will be essential to defining and driving our marketing
and branding initiatives for Auryxia,” said Greg Madison, chief
executive officer of Keryx Biopharmaceuticals. “He is the right
person to help us make Auryxia the phosphate binder brand of choice
in dialysis. Additionally, Doug’s deep understanding of chronic
kidney disease (CKD) will be important to develop the optimal brand
strategy and positioning of Auryxia for potential expansion as a
treatment for iron deficiency anemia in people with CKD not yet on
dialysis.”
Mr. Jermasek and Keryx’s vice president of sales, Tony Chambers,
who joined the company in August 2015, will report to Mr. Madison
and will join the company’s senior management team. Mr. Jermasek
and Mr. Chambers each bring extensive experience in the
pharmaceutical industry, including expertise in building
successful, results-oriented commercial organizations.
Mr. Madison continued, “Since joining Keryx, Tony efficiently
and effectively executed our field force expansion and has
implemented programs for our field-based teams that are driving
adoption of Auryxia. He joined Keryx at a critical time in the
launch of this medicine. His pragmatism, coupled with a sense of
urgency and results-driven approach have contributed significantly
to the turnaround of Auryxia. The complementary backgrounds and
expertise of Doug and Tony are a great asset for Keryx.”
About Douglas JermasekMr. Jermasek has more
than 20 years of biopharmaceutical strategic marketing experience.
Prior to joining Keryx, from 2002 to 2014, he had commercial roles
of increasing responsibility within Genzyme/Sanofi's global renal
business, culminating in 2012 when he was appointed to the role of
senior vice president & general manager of that business. After
his tenure at Genzyme/Sanofi, he held senior leadership roles at
Deltanoid Pharmaceuticals and Intercept Pharmaceuticals. Earlier in
his career, Mr. Jermasek held positions at Hybritech/Lilly, Abbott
Laboratories, Agouron/Pfizer, and Prometheus. Mr. Jermasek received
an M.B.A. from the Marriott School of Management and a B.S. in
biological science from Brigham Young University.
About Tony ChambersMr. Chambers joined Keryx
Biopharmaceuticals in August 2015 bringing approximately 30 years
of sales experience in biopharmaceutical and medical device
industries, including a track record of establishing high
performing field based teams, and developing and executing
commercial sales plans in competitive environments. Prior to Keryx,
Mr. Chambers spent nearly two years as vice president of sales at
Cubist before it was acquired by Merck. Mr. Chambers has also
consulted to large and small biotechnology and pharmaceutical
companies, focused on sales force effectiveness. He spent
approximately 16 years in numerous roles of increasing
responsibility at Genzyme/Sanofi US Biosurgery business, including
vice president of sales and vice president of international. Prior
to Genzyme, he spent more than 12 years at Acufex, a medical device
company now part of Smith & Nephew, where he held a number of
leadership positions, including a divisional manager. Mr. Chambers
received a B.S. in physical therapy from the University of
Connecticut.
About Keryx Biopharmaceuticals, Inc. Keryx
Biopharmaceuticals, with headquarters in Boston, is focused on
bringing innovative medicines to people with renal disease. In
December 2014, the company launched its first FDA-approved
medicine, Auryxia® (ferric citrate) in the United States. In
January 2014, ferric citrate was approved for use in Japan, where
it is being marketed as Riona® by Keryx's Japanese partner, Japan
Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015,
the European Commission granted European market authorization for
Fexeric® (ferric citrate coordination complex). For more
information about Keryx, please visit www.keryx.com.
Forward-Looking Statements Some of the
statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Among the factors that could cause
our actual results to differ materially are the following: the risk
that we may not be able to successfully market Auryxia in the U.S.
for patients with chronic kidney disease on dialysis; the risk that
the FDA may not concur with our interpretation of our Phase 3 study
results, supportive data, conduct of the studies, or any other part
of our regulatory submission and could ultimately deny approval of
the ferric citrate for the treatment of iron deficiency anemia
(IDA) in adults with stage 3-5 non-dialysis dependent (NDD) chronic
kidney disease (CKD), and other risk factors identified from time
to time in our reports filed with the Securities and Exchange
Commission. Any forward looking statements set forth in this press
release speak only as of the date of this press release. We do not
undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof.
This press release and prior releases are available at
http://www.keryx.com. The information found on our website is not
incorporated by reference into this press release and is included
for reference purposes only.
KERYX BIOPHARMACEUTICALS CONTACTS:
Amy Sullivan
Vice President, Corporate Development and Public Affairs
T: 617.466.3519
amy.sullivan@keryx.com
Lora Pike
Senior Director, Investor Relations
T: 617.466.3511
lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024